When I discovered that Fosamax belonged to the same family of drugs as those employed in chemotherapy treatments and that these class of drugs were thought to cause osteonecrosis, I wanted to know why Merck hadn’t come forward with that knowledge. Well, as Merck has shown in its defense of Vioxx, the company is more concerned with profits than people. In the midst of the news reports about Fosamax this week, Merck spokespeople keep insisting there is no link between the drug and osteonecrosis. Yet they never offer to investigate or do something to protect the consumer taking Fosamax. In the final analyisis, it’s difficult to trust these huge pharmaceutical companies.